Showing 2361-2370 of 5909 results for "".
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- Roche Stops Clinical Development of Oral Drug Candidate for Diabetic Retinopathyhttps://modernod.com/news/roche-stops-clinical-development-of-oral-drug-candidate-for-diabetic-retinopathy/2481902/Roche has decided to stop development of vicasinabin, an oral drug cadidate being evaluated for non-proliferative diabetic retinopathy, after completing phase 2 trials, according to a FiercePharma
- Lighthouse Guild to Host Lectures on Ophthalmic Drug Approvals, Technological Innovations, and Advocacy for People with Vision Impairmenthttps://modernod.com/news/lighthouse-guild-to-host-lectures-on-ophthalmic-drug-approvals-technological-innovations-and-advocacy-for-people-with-vision-impairment/2481898/Lighthouse Guild will host three lectures on the latest advances in treatment, technology, and advocacy for people who are blind or have vision loss on Thursday, October 19, 2023, 12-1:30 pm ET, at their headquarters, 250 West 64th Street in Manhattan. Lectures:
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of
- Staar Surgical Celebrates 30th Anniversary of Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-30th-anniversary-of-implantable-collamer-lens-icl/2481892/Staar Surgical is celebrating the 30th anniversary of its proprietary Implantable Collamer Lens (ICL). The first ICLs were implanted by a group of surgeons in October 1993, including Roberto Zaldivar, MD, Founder of the Zaldivar Institute. The early ICLs have evolved into the curre
- RSC Survey Shows Travelers Relying on Glasses and Contact Lenses Have Vacation FOMOhttps://modernod.com/news/rsc-survey-shows-travelers-relying-on-glasses-and-contact-lenses-have-vacation-fomo/2481887/A new poll commissioned by the Refractive Surgery Council (RSC) reveals 50% of Americans with vision prescriptions missed out on at least one activity from their vacation because they wear glasses or contacts. As a result of their ‘vacation FOMO,’ 55% believe having vision c
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-presents-data-at-academy23-on-acuvue-max-1-day-contact-lenses/2481885/Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14. In celebration
- Alcon Showcases New TOTAL30 Multifocal Lenses and Other Innovations at #Academy23https://modernod.com/news/alcon-demonstrates-commitment-to-innovation-at-academy23-showcasing-total30-multifocal/2481884/Alcon will introduce TOTAL30 Multifocal, the first and only reusable Water Gradient multifocal contact lens, along with the latest advancements in eye care technology at the American Academy of Optometry Annual Meeting (#Academy23) in New Orleans, October 11-14, 2023. Alcon&rs
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an